Last reviewed · How we verify
NCT05385575
A Study to Evaluate Effects of KN056 in Healthy Participants
Phase 1 trial testing KN056 (0.1mg) in Type 2 Diabetes in 46 participants. Completed in 29 February 2024.
22 December 2023
Quick facts
| Lead sponsor | Suzhou Alphamab Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 9 August 2022 |
| Primary completion | 22 December 2023 |
| Estimated completion | 29 February 2024 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- KN056 (0.1mg) — full drug profile →
- KN056 (0.3mg)
- KN056 (1.0mg)
- KN056 (3.0mg) — full drug profile →
- KN056 (6.0mg) — full drug profile →
- KN056 (12.0mg) — full drug profile →
- KN056 (18.0mg) — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Suzhou Alphamab Co., Ltd. — full company profile →
Who can join
Adults 18 to 55, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN056 in healthy participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05385575
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Suzhou Alphamab Co., Ltd. trials
Trials by the same sponsor.
- NCT06747416 — KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors · Phase 2 · not yet recruiting
- NCT07201467 — To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients · Phase 1, PHASE2 · recruiting
- NCT07191899 — To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension · Phase 1 · recruiting
- NCT06547775 — A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight · Phase 1 · recruiting
- NCT06569108 — Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05385575 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Alphamab Co., Ltd.
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05385575.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing